The Business Research Company's Human Respiratory Syncytial Virus Treatment Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 The Business Research Company's Latest ...

The global respiratory syncytial virus respiratory syncytial virus treatment market is undergoing rapid growth, driven by rising vaccine uptake, impr ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

As winter settles over Australia, it's not just the drop in temperature we notice—there's also a sharp rise in respiratory ...

Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...

MPV tends to hit hardest in young children, older adults and people with weakened immune systems. A virologist explains.

THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial ...

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

HMPV is a relatively recent discovery in human respiratory viruses and, like Respiratory Syncytial Virus (RSV), can cause conditions ranging from asymptomatic infection to severe bronchiolitis.

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...

No writing assistance was utilized in the production of this manuscript. Worldwide, respiratory syncytial virus (RSV) is the most important cause of bronchiolitis and pneumonia in infants.

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...